Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
8Customers
3Debt Items
2Related Chains
Source-Backed Evidence Depth
IO Biotech, Inc. (IOBT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
1Distinct source URLs
6High confidence
0.757Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
IO Biotech, Inc. Suppliers
Ticker
Name
Confidence
Evidence
MSD-INTERNATIONAL-BUSINESS-GMBH
MSD-INTERNATIONAL-BUSINESS-GMBH
92%
MSDIB provided KEYTRUDA® to be used in the clinical trial free of charge
MSD-INTERNATIONAL-GMBH
MSD-INTERNATIONAL-GMBH
92%
MSDIG provided KEYTRUDA® to be used in the clinical trial free of charge
Reciprocal relationship from IOBTQ graph: Reciprocal relationship from IOBT graph: Reciprocal relationship from IOBTQ graph: Reciprocal relationship from IOBT graph: Reciprocal relationship from IOBT…
age in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading. We are exposed to the risk of fraud or other misconduct by our…
COMPANY-LLC
COMPANY-LLC
62%
sses resulting from research and development costs of up to 25 million Danish Kroner per year. The tax credit is presented as a reduction to research and development expense in the consolidated state…
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
asdaq listing deficiencies which may occur in the future. If Nasdaq delists our common stock, it is unlikely that we will be able to list our common stock on another national securities exchange and,…
EMERGING-GROWTH-COMPANY
EMERGING-GROWTH-COMPANY
62%
ly expect that our cash and cash equivalents of $30.7 million as of September 30, 2025 will not be sufficient to fund our operating expenses and capital requirements for at least 12 months from the d…
IO-BIOTECH-APS-IO-BIO-US-INC
IO-BIOTECH-APS-IO-BIO-US-INC
62%
age in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading. We are exposed to the risk of fraud or other misconduct by our…
IO-BIOTECH-LIMITED
IO-BIOTECH-LIMITED
62%
age in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading. We are exposed to the risk of fraud or other misconduct by our…
ONO-PHARMACEUTICAL-CO-LTD
ONO-PHARMACEUTICAL-CO-LTD
62%
age in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading. We are exposed to the risk of fraud or other misconduct by our…
IO Biotech, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
IOBT-DEBT-10324
Warrants outstanding: -7259000
90%
xbrl warrant detail from xbrl 2025-09-30.
IOBT-DEBT-10325
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
IOBT-DEBT
Debt stack $18.1M
90%
Market cache reports total debt of $18.1M.
IO Biotech, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for IO Biotech, Inc..
IO Biotech, Inc. Ownership
Holder
Name
Confidence
Evidence
IOBT-OWNER-MORGAN-STANLEY
MORGAN STANLEY
90%
13F overlay lists MORGAN STANLEY as top holder; 13 tracked holders.
